undamentalytics Newsletter
Sign in

National Healthcare Corp (NHC) stock

Add to watchlist

Add holding +

NYSE: NHC NYSE Health Care Facilities Next results ~November 6, 2026

B Fundamentals grade

National Healthcare Corp is a US-listed company in the health care facilities industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: our cash-flow value ($217.20) was left out of our combined valuation (it is more than 3x away from the median of our other models), so it can't be the basis of a rating.

Price vs value

Under review: our cash-flow value ($217.20) was left out of our combined valuation (it is more than 3x away from the median of our other models), so it can't be the basis of a rating. We'll show the comparison once resolved.

National Healthcare Corp valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 9 selling1 purchase and 23 sales by directors and officers, last 12 monthsInsider trades
  • Funds129 adding, 100 cuttingOf 33 active managers that changed their stake, 17 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter National Healthcare files

Where National Healthcare stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $1.56bn, up 6.9% on a year earlier, slower than the 10.3% growth a quarter earlier. Free-cash-flow margin rose to 9.4% from 8.2% a year earlier. Against its peers on growth, profitability, cash generation and balance sheet, it grades B. It passes 6 of our 6 financial-health checks. At that price, our model says the market is pricing in about 10.6% a year of cash-flow growth for five years, faster than the 7.7% a year revenue growth it has delivered.

Our model value for National Healthcare is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 6, 2026 (estimated)

National Healthcare Corp's trailing-twelve-month revenue grew 6.9% year on year, with a free-cash-flow margin of 9.4%. Where it stands out: long-term debt as % of assets of 0.0% ranks 1 of 13 health care facilities companies we cover. Where it lags: change in growth rate of -3.3pp ranks 11 of 13 health care facilities companies we cover.

Our discounted-cash-flow model values the business at ~$220 per share in the base case (~$160–$290 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Revenue growth decelerating: TTM revenue growth slowed to 6.9% (-3.3pp vs the prior quarter), the 4th consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in National Healthcare Corp's latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 6 November; the share price can move sharply on the day.
  • Growth easing. The growth rate is 3.3 points lower than a quarter earlier.
  • Below peers: change in growth rate. Change in growth rate of -3.3pp ranks 11 of 13 health care facilities companies we cover (median -1.4pp).

Latest results: FY2026 Q2

Filed August 6, 2026
Revenue
$408m, up 8.8% on a year earlier
Share reaction
+0.3% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500
Next report
November 6, 2026

National Healthcare's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.6%
  • 1 week-4.0%
  • 1 month-10.7%
  • This year+48.9%
  • 1 year+70.5%
  • 5 years+226.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$1.6B
Operating margin
9.3%
Net margin
9.0%
EPS (TTM, diluted)
$8.90

Growth

Revenue growth
+6.9%
Change in growth rate
−3.3 pts
Share count change
+0.9%

Cash

Free cash flow (TTM)
$147M
FCF margin
9.4%
Stock pay % of revenue
0.3%

Earnings

Last results
August 11, 2026
Next results (est.)
November 6, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Insider trade
  2. Insider trade
  3. Results
  4. Dividend
  5. Announcement
  6. Results
  7. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

National Healthcare Corp valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: held for review: our cash-flow value ($217.20) was left out of our combined valuation (it is more than 3x away from the median of our other models), so it can't be the basis of a rating.

Our value per share comes from a discounted-cash-flow model of National Healthcare Corp's free cash flow after stock-based pay ( $130M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value National Healthcare Corp as an operating company, with every model that fits that kind of business. Cost of equity 8.3%: the 10-year Treasury yield (4.9%) plus a beta of 0.74 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$220 ~$160–$290 Left out: far from the other models (more than 3x away from their median)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. ~$1.2 ~$80–$240 Left out: out of range vs price (0.01x)
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$71 ~$50–$100 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$70 ~$59–$86 Included
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare National Healthcare Corp with Health Care Facilities in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$57.97$47.96$63.51$71.78$56.96$60.03$54.37$87.45$104.11$135.70$202.09
Market value$882m$730m$968m$1.1bn$875m$925m$840m$1.3bn$1.6bn$2.1bn$3.2bn
+ Net debt (− = net cash)$94m$41m$12m−$40m−$147m−$108m−$59m−$107m$61m−$53m−$39m
Enterprise value$975m$771m$979m$1.1bn$728m$818m$781m$1.2bn$1.7bn$2.1bn$3.1bn
Multiples
Price / sales 1.0x0.8x1.0x1.1x0.9x0.9x0.8x1.2x1.2x1.4x2.0x
Price / earnings 17.4x13.0x16.4x16.2x20.9x6.7x37.4x20.1x15.9x17.7x22.7x
Price / free cash flow 31.2x11.8x14.1x15.0x4.8x40.2x—16.1x20.4x14.3x21.7x
EV / EBITDA 9.8x8.0x10.0x11.6x8.1x8.9x10.8x12.4x12.8x11.9x16.5x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

55 /100

Moderate moat

How hard National Healthcare's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 7 / 20

    Net income has been a median 5.3% of total assets over 10 years.

  • Durability 9 / 20

    Operating margin has been a median 5.5%; its worst year was 3.4%.

  • Cash conversion 13 / 20

    Free cash flow was positive in 8 of 9 years, at a median 7.4% of revenue.

  • Discipline 16 / 20

    The diluted share count rose 2.3% over five years; stock-based pay has been a median 0.2% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 6, 2026, before the open.

Analysts' consensus

No analyst estimates are published for National Healthcare Corp: too few analysts cover it.

Positioning

Short interest
6.4%
of tradable shares
Days to cover
7.58
at average volume
Short interest, 1 month
+9%
to September 30, 2026
Held by institutions
67%
of shares
Held by insiders
18.8%
of shares
Employees
15,278
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +71.7%

$117.68 on October 31, 2025 to $202.09

ThenNowEffect
Revenue (last 12 months) $1.5bn $1.6bn +6.9%
Net margin 7.2% 9.0% +25.2%
P/E multiple 17.5x 22.7x +29.4%
Share count 16m 16m −0.9%

Biggest factor: p/e multiple.

Last 3 years +203.0%

$66.70 on November 3, 2023 to $202.09

ThenNowEffect
Revenue (last 12 months) $1.1bn $1.6bn +43.4%
Net margin 2.9% 9.0% +206.5%
P/E multiple 32.1x 22.7x −29.3%
Share count 15m 16m −2.4%

Biggest factor: net margin.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
NHC+5%−9%+61%+19%+30%+49%
Industry peers (median)+21%−6%+9%+12%+31%+4%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
NHC42%42%67%58%67%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
NHC−18%−20%−16%−21%−16%−19%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 35% from January 8, 2020 to March 16, 2020. Getting back needed a 55% gain, reached on December 4, 2023, 1358 days after the low.

Price behaviour

52-week range
$119.26 – $247.94
From 52-week high
−18.5%
vs 50-day average
−10.2%
vs 200-day average
+4.5%
Volatility (1 year)
35%
Beta vs S&P 500
0.23

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
11 up, 1 down
typical move ±4.5%
After a week
11 up, 1 down
typical move ±7.0%
After a month
11 up, 1 down
typical move ±8.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 11, 2026 +0.3% −0.1% +5.9% +1.8%
May 8, 2026 +10.7% +1.1% +13.0% +12.1%
February 27, 2026 +6.9% −0.4% +4.8% +1.4%
November 7, 2025 +4.6% +1.7% +2.5% +7.1%
August 8, 2025 +7.3% +0.6% +11.5% +18.3%
May 9, 2025 +7.9% +3.2% +14.7% +10.3%
February 27, 2025 +0.6% −0.1% +1.4% +0.5%
November 12, 2024 −4.4% −0.3% −8.2% −11.3%
August 9, 2024 +3.2% +0.5% +4.9% +2.2%
May 10, 2024 +0.9% +0.1% +4.6% +7.7%
February 16, 2024 +5.8% −1.0% +6.9% +0.4%
November 3, 2023 +1.8% +1.1% +5.7% +27.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

National Healthcare Corp in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) National Healthcare Corp
$1B $1.2B $1.4B $1.6B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $1.1B Revenue (TTM), FY23 Q4: $1.1B Revenue (TTM), FY24 Q1: $1.2B Revenue (TTM), FY24 Q2: $1.2B Revenue (TTM), FY24 Q3: $1.2B Revenue (TTM), FY24 Q4: $1.3B Revenue (TTM), FY25 Q1: $1.4B Revenue (TTM), FY25 Q2: $1.5B Revenue (TTM), FY25 Q3: $1.5B Revenue (TTM), FY25 Q4: $1.5B Revenue (TTM), FY26 Q1: $1.5B Revenue (TTM), FY26 Q2: $1.6B $1.6B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $1.1B
FY23 Q4 $1.1B
FY24 Q1 $1.2B
FY24 Q2 $1.2B
FY24 Q3 $1.2B
FY24 Q4 $1.3B
FY25 Q1 $1.4B
FY25 Q2 $1.5B
FY25 Q3 $1.5B
FY25 Q4 $1.5B
FY26 Q1 $1.5B
FY26 Q2 $1.6B
Revenue growth, TTM YoY National Healthcare Corp
0% 10% 20% 30% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 0.1% Revenue growth, TTM YoY, FY23 Q4: 5.1% Revenue growth, TTM YoY, FY24 Q1: 8.6% Revenue growth, TTM YoY, FY24 Q2: 9.2% Revenue growth, TTM YoY, FY24 Q3: 12.1% Revenue growth, TTM YoY, FY24 Q4: 14.5% Revenue growth, TTM YoY, FY25 Q1: 18.4% Revenue growth, TTM YoY, FY25 Q2: 22.8% Revenue growth, TTM YoY, FY25 Q3: 21.1% Revenue growth, TTM YoY, FY25 Q4: 16.1% Revenue growth, TTM YoY, FY26 Q1: 10.3% Revenue growth, TTM YoY, FY26 Q2: 6.9% 6.9%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 0.1%
FY23 Q4 5.1%
FY24 Q1 8.6%
FY24 Q2 9.2%
FY24 Q3 12.1%
FY24 Q4 14.5%
FY25 Q1 18.4%
FY25 Q2 22.8%
FY25 Q3 21.1%
FY25 Q4 16.1%
FY26 Q1 10.3%
FY26 Q2 6.9%
Operating margin (TTM) National Healthcare Corp
4% 6% 8% 10% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 4.2% Operating margin (TTM), FY23 Q4: 5.0% Operating margin (TTM), FY24 Q1: 5.4% Operating margin (TTM), FY24 Q2: 6.0% Operating margin (TTM), FY24 Q3: 6.6% Operating margin (TTM), FY24 Q4: 6.9% Operating margin (TTM), FY25 Q1: 7.6% Operating margin (TTM), FY25 Q2: 8.0% Operating margin (TTM), FY25 Q3: 8.3% Operating margin (TTM), FY25 Q4: 8.5% Operating margin (TTM), FY26 Q1: 8.5% Operating margin (TTM), FY26 Q2: 9.3% 9.3%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 4.2%
FY23 Q4 5.0%
FY24 Q1 5.4%
FY24 Q2 6.0%
FY24 Q3 6.6%
FY24 Q4 6.9%
FY25 Q1 7.6%
FY25 Q2 8.0%
FY25 Q3 8.3%
FY25 Q4 8.5%
FY26 Q1 8.5%
FY26 Q2 9.3%
FCF margin (TTM) National Healthcare Corp
6% 8% 10% 12% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 6.6% FCF margin (TTM), FY23 Q4: 7.3% FCF margin (TTM), FY24 Q1: 6.8% FCF margin (TTM), FY24 Q2: 7.5% FCF margin (TTM), FY24 Q3: 7.4% FCF margin (TTM), FY24 Q4: 6.1% FCF margin (TTM), FY25 Q1: 7.9% FCF margin (TTM), FY25 Q2: 8.2% FCF margin (TTM), FY25 Q3: 9.8% FCF margin (TTM), FY25 Q4: 9.8% FCF margin (TTM), FY26 Q1: 11.0% FCF margin (TTM), FY26 Q2: 9.4% 9.4%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 6.6%
FY23 Q4 7.3%
FY24 Q1 6.8%
FY24 Q2 7.5%
FY24 Q3 7.4%
FY24 Q4 6.1%
FY25 Q1 7.9%
FY25 Q2 8.2%
FY25 Q3 9.8%
FY25 Q4 9.8%
FY26 Q1 11.0%
FY26 Q2 9.4%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 924 964 980 996 1,028 1,074 1,086 1,142 1,307 1,518 1,559
EBITDA 100 97 98 91 90 92 72 99 132 173 190
Operating income 61 54 56 49 48 51 32 57 90 128 145
Net income 51 56 59 68 42 139 22 67 102 120 140
Diluted EPS $3.32 $3.69 $3.87 $4.44 $2.72 $8.99 $1.45 $4.34 $6.53 $7.67 $8.90
Growth (year on year)
Revenue — +4.4% +1.7% +1.6% +3.2% +4.5% +1.1% +5.1% +14.5% +16.1% +6.9%
EBITDA — −2.8% +1.2% −6.6% −1.4% +1.6% −21.0% +37.4% +32.6% +31.4% +18.5%
Operating income — −10.6% +3.6% −12.6% −1.8% +5.8% −37.4% +80.1% +56.5% +42.8% +24.1%
Net income — +11.2% +4.9% +15.7% −38.6% +231.0% −83.8% +197.6% +52.6% +17.7% +33.8%
Diluted EPS — +11.1% +4.9% +14.7% −38.7% +230.5% −83.9% +199.3% +50.5% +17.5% +32.7%
Margins
EBITDA margin 10.8% 10.0% 10.0% 9.2% 8.8% 8.5% 6.7% 8.7% 10.1% 11.4% 12.2%
Operating margin 6.6% 5.6% 5.7% 4.9% 4.7% 4.7% 2.9% 5.0% 6.9% 8.5% 9.3%
Net margin 5.5% 5.8% 6.0% 6.8% 4.1% 12.9% 2.1% 5.9% 7.8% 7.9% 9.0%
Free-cash-flow margin 3.1% 6.4% 7.0% 7.4% 17.6% 2.1% −2.0% 7.3% 6.1% 9.8% 9.4%
Cash flow
Cash from operations 91 94 98 100 203 62 9 111 107 185 189
Capital spending 63 32 30 26 22 39 30 28 28 36 42
Free cash flow 28 62 69 74 181 23 −21 83 80 149 147
Stock-based pay 1 2 2 2 2 3 3 3 4 4 5
Free cash flow after stock pay 28 60 67 72 179 20 −24 81 76 144 141
Balance sheet
Cash 26 59 43 50 147 108 59 107 76 93 39
Total debt 120 100 55 10 0 0 0 0 137 40 0
Net debt (negative = net cash) 94 41 12 −40 −147 −108 −59 −107 61 −53 −39
Diluted shares 15m 15m 15m 15m 15m 15m 15m 15m 16m 16m 16m
Returned to shareholders
Dividends 26 28 30 31 32 32 35 36 37 39 40
Buybacks 8 0 1 1 0 1 10 2 14 15 32
Total returned 34 28 31 32 32 33 45 38 50 53 72

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

6 of 6 checks passed · June 30, 2026
What it owns · $1.5bn
Short-term assets $440mLonger-term assets $1.1bn
What it owes, and who funded it · $1.5bn
Short-term liabilities $236mLonger-term liabilities $173mShareholders' equity $1.1bn
  • Short-term assets cover short-term liabilities $440m of assets due within a year against $236m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $440m short-term assets against $173m of longer-dated liabilities.
  • More cash than debt $39m of cash against $0 of debt.
  • Debt below 40% of shareholders' equity Debt is 0% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt No debt to cover.
  • Operating profit covers interest at least five times over Operating income of $145m against $3m of interest.

From National Healthcare Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q2 TTM
Buybacks (TTM)
$31.9M
Dividends (TTM)
$39.8M
Returned to shareholders
49%
of free cash flow
Buybacks, last 3 fiscal years
$30.7M
Diluted share count
+0.9%
year over year
Total shareholder yield
2.3%
dividends 1.3% + buybacks 1.0% of market value
Dividend payout ratio
28%
of net income paid out
Days sales outstanding
32 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care facilities
Last 12 months unless stated NHC CON BKD SGRY ACHC SNDA Median
Revenue, last 12 months $1.6bn $2.3bn $3.1bn $3.4bn $3.4bn $526m $3.1bn
Revenue growth, last 12 months 6.9% 14.0% −4.4% 4.0% 4.3% 49.4% 14.0%
Revenue growth, 3-year average 12.8% — 1.0% 8.1% 6.6% 29.0% 8.1%
Revenue growth, latest quarter 8.8% 10.0% −11.6% 2.7% −0.4% 122.0% 8.6%
Gross margin — — 26.9% 23.1% — — 21.2%
Operating margin 9.3% 16.4% 3.5% 11.4% 28.7% −3.3% 9.0%
Operating margin, 3-year average 7.8% 15.9% 1.8% 11.5% 23.7% 0.0% 7.9%
Net margin 9.0% 8.7% −4.5% −2.6% −33.4% −23.3% 4.8%
Cash from operations / revenue 12.1% 14.7% 7.3% 7.7% 6.3% −3.0% 7.7%
Free-cash-flow margin 9.4% 11.7% 0.8% 5.6% −4.0% −10.0% 4.7%
Free-cash-flow margin, 3-year average 8.4% 10.2% −0.5% 6.0% −9.5% −6.9% 5.9%
Stock pay / revenue 0.3% 0.6% 0.4% 0.3% 0.9% 1.4% 0.6%
Change in share count 0.9% 1.6% 3.7% 1.3% −1.1% 57.5% 0.9%

Median of all 13 companies we cover in health care facilities. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

13 health care facilities companies
Measure Company Peer median Rank
Revenue growth Growth 6.9% 14.0% 9 of 13
Change in growth rate Growth -3.3pp -1.4pp 11 of 13
Operating margin Profitability 9.3% 9.0% 4 of 9
Net margin Profitability 9.0% 4.8% 2 of 13
Free-cash-flow margin Cash generation 9.4% 4.7% 3 of 13
Stock pay as % of revenue Cash generation 0.3% 0.6% 3 of 12
Long-term debt as % of assets Balance sheet 0.0% 37.7% 1 of 13
Change in share count Balance sheet 0.9% 0.9% 7 of 13
Days sales outstanding Balance sheet 32 days 48 days 3 of 12

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue YoY
Inpatient Services $1.3B ▲ 18.4%
Homecare Services $154M ▲ 9.7%

These categories overlap or exclude eliminations, so shares aren't shown.

From National Healthcare Corp's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$2.2B
Institutions reporting
248
Shares held vs prior quarter
▼ 1.1%
Positions opened / closed
36 / 25

Top buyers and sellers, Q2 2026: 129 institutions bought and 100 sold ; the biggest buyer was First Trust Advisors LP (+200K shares) and the biggest seller M Holdings Securities, Inc (−462K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $418M 2.0M 19.3% ▲ 4.2%
Morgan Stanley Institutional Investment Advisors LLC $217M 1.0M 10.1% ▼ 1.0%
Dimensional Fund Advisors LP $196M 930K 9.1% ▼ 1.8%
Vanguard Portfolio Management LLC $171M 809K 7.9% ▲ 2.5%
First Trust Advisors LP $154M 731K 7.1% ▲ 37.8%
Vanguard Capital Management LLC $117M 552K 5.4% ▲ 0.5%
State Street Corp $112M 527K 5.2% ▲ 7.2%
Geode Capital Management, LLC $80.5M 381K 3.7% ▲ 17.8%
Renaissance Technologies LLC $63.3M 300K 2.9% ▼ 10.7%
Invesco Ltd. $37M 175K 1.7% ▲ 16.7%
Charles Schwab Investment Management Inc $36.8M 174K 1.7% ▼ 2.4%
Northern Trust Corp $30.7M 145K 1.4% ▲ 6.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not National Healthcare Corp's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $174,863 1 trade by 1 insider, last 12 months Insider sales History → $11.2M 23 trades by 9 insiders · 0% under pre-set plans
Net ▼ $11M net selling
Insider Date Trade Shares Price Value
Dodson Vicki L Sr.VP Patient Srvcs September 22, 2026 Sell 4,834 $225.00 $1.1M
Kidd Brian F SVP, CFO September 11, 2026 Sell 6,813 $225.70 $1.5M
Mccreary Josh A Senior VP & General Counsel September 10, 2026 Sell 68 $225.59 $15,340
Mccreary Josh A Senior VP & General Counsel September 10, 2026 Sell 571 $222.73 $127,179
Mccreary Josh A Senior VP & General Counsel September 10, 2026 Sell 789 $223.78 $176,562
Mccreary Josh A Senior VP & General Counsel September 10, 2026 Sell 1,291 $225.09 $290,591
Flatt Ben Anderson Sr Senior VP & CIO August 28, 2026 Sell 1,000 $222.50 $222,500
Gifford David R. Director August 25, 2026 Sell 1,779 $225.42 $401,022
Flatt Ben Anderson Sr Senior VP & CIO August 25, 2026 Sell 1,000 $227.00 $227,000
Flatt Ben Anderson Sr Senior VP & CIO August 20, 2026 Sell 1,000 $237.00 $237,000
Flatt Stephen Fowler CEO August 19, 2026 Sell 1,500 $237.08 $355,620
Flatt Ben Anderson Sr Senior VP & CIO August 19, 2026 Sell 1,000 $237.18 $237,180

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 6, 2026 estimated from the company's past filing pattern, not announced

  • August 11, 2026
  • May 8, 2026
  • February 27, 2026
  • November 7, 2025
  • August 8, 2025
  • May 9, 2025

Recent SEC filings

Data status

When each part of this page on National Healthcare Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

National Healthcare Corp in brief

What does National Healthcare Corp do?
National Healthcare Corp is a US-listed company in the health care facilities industry. Its financial year ends in December.
What is National Healthcare Corp's stock ticker?
National Healthcare Corp trades under the ticker NHC on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is National Healthcare Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, National Healthcare Corp reported revenue of $1.6B, 6.9% higher than a year earlier, according to its SEC filings.
What is National Healthcare Corp's free cash flow?
National Healthcare Corp's free-cash-flow margin is 9.4% of revenue over the trailing twelve months, ranking 3 of the 13 health care facilities companies we cover.
Who are National Healthcare Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Morgan Stanley Institutional Investment Advisors LLC and Dimensional Fund Advisors LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is National Healthcare Corp buying back stock, and does it pay a dividend?
National Healthcare Corp spent $31.9M on share repurchases over the trailing twelve months, and its diluted share count still rose 0.9% over the year.
What is National Healthcare Corp's market cap?
On November 2, 2026, National Healthcare Corp's market capitalisation was about $3.2B, with a price-to-earnings ratio of 22.7 and net debt of -$39.2M. Market figures come from third-party market data and may be delayed.
Does National Healthcare Corp pay a dividend?
Yes: National Healthcare Corp paid $39.8M in dividends over the trailing twelve months, a dividend yield of 1.26% and a payout ratio of 28.4%.
How much debt does National Healthcare Corp have?
National Healthcare Corp's debt-to-equity ratio is 0.0%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are National Healthcare Corp's competitors?
In our Health Care Facilities peer group, the companies closest to National Healthcare Corp are Concentra Group Holdings Parent, Inc., Brookdale Senior Living Inc., Surgery Partners, Inc., Acadia Healthcare Company, Inc. and Sonida Senior Living, Inc. The side-by-side comparison below sets their revenue, margins and growth against National Healthcare Corp's.
Are insiders buying or selling National Healthcare Corp stock?
Over the last 12 months, National Healthcare Corp's directors and officers reported 1 open-market purchases and 23 sales on Form 4. The insider trading page charts every trade.
When is National Healthcare Corp's next earnings date?
Around November 6, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — National Healthcare Corp announces its own schedule.